Clinical pharmacokinetics of depot leuprorelin

Clinical Pharmacokinetics

Volumn 41, Issue 7, 2002, Pages 485-504

  Periti, Piero ^a   Mazzei, Teresita ^a   Mini, Enrico ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LEUPRORELIN; POLYGLYCOLIC ACID; POLYLACTIC ACID; POLYMER;

AREA UNDER THE CURVE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; HUMAN; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SUSTAINED RELEASE PREPARATION;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; DELAYED-ACTION PREPARATIONS; HALF-LIFE; HUMANS; LEUPROLIDE; MALE; MICROSPHERES; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 0036073843     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200241070-00003     Document Type: Review

References (70)

1. Hypophysiological responses to continuous and intermittent delivery of hypothatamic gonadotropin-releasing hormone
2. Gonadotropin-releasing hormone and its analogues: From laboratory to bedside
3. Luteinizing hormone release and gonadotropin-releasing hormone (GnRH) receptor internalization independent actions of GnRH
4. Desensitization of pituitary gonadotropin secretion by agonist-induced inactivation of voltage-sensitive calcium channels
5. Gonadotropin-releasing hormone and its analogues
6. Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: Rationale and perspective
7. Pharmacokinetics of anti-endocrine agents
8. Synthetic analogs of luteinizing hormone-releasing hormone (LH-RH) substituted in position 6 and 10
9. Pharmacokinetics of gonadotropin-releasing hormone and its analogs
10. Leupeorelin. A review of its pharmacological and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders
11. Adenohypophyseal hormones and their hypothalamic releasing factors
12. Percutaneous absorption enhancement of leuprolide
13. Radioligand assay for gonadotropin-releasing hormone: Relative potencies of agonists and antagonists
14. Leuprorelin acetate depot in advanced prostatic cancer: A phase II multicenter trial
15. A phase II study of leuprolide in advancad/recurrent endometrial cancer
16. A randomized comparison of the clinical and hormonal effects of two GnRH agonists in patients with prostate cancer
17. A pilot study of intermittent androgen deprivation in advanced prostate cancer
18. Leuprorelide acetate depot and hormonal add back in endometriosis: A 12-month study
19. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer
20. Leuprolide acetate 22.5 mg 12-week depot formulation in the treatment of patients with advanced prostate cancer
21. Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer
22. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer
23. Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: Long-term follow-up results
24. Safety and efficacy of an implamable leuprolide delivery system in patients with advanced prostate cancer
25. Evaluation of an implant that delivers leuprolide for 1 year for the palliative treatment of prostate cancer
26. Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration
27. In vivo metabolism of tritiated LHRH by the whole kidney and individual tubules of rats
28. Bioavailability of leuprolide acetate following nasal inhalation delivery to rats and healthy humans
29. Leuprorelin: A review of its pharmacology and therapeutic use in prostatic disorders
30. Sublingual absorption of leuprolide: Comparison between human and animal models
31. Drug delivery using biodegradable microspheres
32. Biodegradable microspheres in drug delivery
33. In vivo release profiles of leuprolide acetate from microcapsules prepared with polylactic acids or copoly(lacdc/glycolic) acids and in vivo degradation of these polymers
34. A new technique to efficiently entrap leuprolide acetate into microcapsules of polyactic acid or copoly(lactic/glycolic) acid
35. Controlled release of LHRH agonish leuprolide acetate, from microcapsules: Serum drug level profiles and pharmacological effects in animals
36. Once-month release injectable microspheres of leuprolide acetate, a superactive agonist of LH-RH
37. One-month release injectable microspheres of leuprolide acetate inhibit steroidogenesis and genital organ growth in rats
38. Extended release peptide delivery systems through the use of PLGA microsphere combinations
39. Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide
40. Sustained suppression of pituitary-gonadal axis with an injectable, in situ forming implant of leuprolide acetate
41. Enhancing initial release of peptide from poly(d,1-lactide-co-glycolide) (PLGA) microspheres by addition of a porosigen and increasing drug load
42. Three-month release injectable microspberes of leuprorelin acetate
43. Preparation of three-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers
44. Sustained suppression of the pituitary-gonadal axis by leuprorelin three-month depot microspheres in rats and dogs
45. Formulation study of leuprorelin acetate to improve clinical performance
46. Controlled-release of leuprolide acetate from polyactic acid or copoly(lactic/glycolic) acid microcapsules: Influence of molecular weight and copolymer ratio of polymer
47. Hydrophobic ion pair formation between leuprolide and sodium oleate for sustained release from biodegradable polymeric microspheres
48. Vaginal absorption of a potent luteinizing hormone-releasing hormone analogue (Leuprolide) in rats. IV: Evaluation of the vaginal absorption and gonadotropth responses by radioimmunoassay
49. Vaginal absorption of a potent luteinizing hormone-releasing hormone analogue (leuprolide) in rats. II: Mechanism of absorption enhancement with organic acids
50. Pharmaceutical aspects: Nasal and depot formulations of leuprolide
51. Seram concentration patterns of an LHRH agonist, gonadotrophins and sex steroids after subcutaneous, vaginal, rectal and nasal administration of the agonist to pregnant rats
52. Successful transdermal administration of therapeutic doses of polypeptide to normal human volunteers
53. One-month release injectable microcapsules of a luteinizing hormone-releasing hormone agonist (leuprolide acetate) for treating experimental endometriosis in rats
54. A radioimmunoassay for a highly active luteinizing hormone-releasing hormone analogue and relation between the serum level of the analogue and that of gonadotropin
55. Pharmacokinetics of once-a-month injectable microspheres of leuprolide acetate
56. Sustained pharmacological activities in rats following single and repeated administration of once-a-month injectable microspheres of leuprolide acetate
57. Persistent suppression of the pituitary-gonadal system in female rats by three month depot injectable microspberes of leuprorelin acetate
58. Clinical study results of the new formulation leuprorelin acetate three-month depot for the treatment of advanced prostate carcinoma
59. Discovery of a novel, potent and orally active nonapeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor
60. The sustained release of LH-RH agonist from LH-RH agonist-polymer composite in patients with prostatic cancer
61. Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: A dose-response evaluation
62. Human pharmacokinetic and pharmacodynamic profiles of leuprorelin acetate depot in prostatic cancer patients
63. An evaluation of pharmacokinetics and phalmaeodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate
64. Leuprolide versus diethylstilbestrol for metastatic prostate cancer
65. High-performance liquid chromatography followed by radioimmunoassay for the determination of aluteinizing hormone-releasing hormone analogue, leuprorelin, and its metabolite
66. 125I]LH-RH suitable for membrane binding studies
67. Interim report of a large French multicentre study of efficacy and safety of 3.75 mg leuprorelin depot in metastatic prostatic cancer
68. Efficacy and safety of leuprorelin acetate depot for prostate eancer
69. Hormonal treatment for prostate cancer